Published in Br J Clin Pharmacol on December 01, 1994
Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ (1999) 7.05
Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax (1996) 1.77
Optimizing inhaled drug delivery in patients with asthma. Br J Gen Pract (1995) 1.70
New perspectives on inhaled drug delivery and systemic bioactivity. Thorax (1995) 1.43
Treatment of isolated gastric Crohn's disease with inhaled corticosteroids. Case Rep Gastroenterol (2008) 0.79
Systemic effects of glucocorticoids--a response. Br J Clin Pharmacol (1995) 0.75
The human pharmacology of fluticasone propionate. Respir Med (1990) 3.50
Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax (1993) 2.81
Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl (1982) 2.59
Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax (1993) 1.87
A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J (1993) 1.84
Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax (1991) 1.79
Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J (1994) 1.59
Bone turnover during high dose inhaled corticosteroid treatment. Thorax (1991) 1.59
Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir Med (1991) 1.25
Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther (1993) 1.20
Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol (1982) 1.18
Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis. Am Rev Respir Dis (1988) 1.18
Effects of dose and dosing schedule of inhaled budesonide on bone turnover. J Allergy Clin Immunol (1991) 1.10
Assessment of systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol (1991) 1.07
A sensitive radioimmunoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma. J Pharm Biomed Anal (1993) 1.05
The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. Br J Clin Pharmacol (1993) 0.96
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med (2001) 7.07
Blood coagulation. Annu Rev Biochem (1980) 4.27
Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet (1995) 2.79
Properties of the factor Xa binding site on human platelets. J Biol Chem (1978) 2.59
Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol (1998) 2.21
The conversion of prothrombin to thrombin. I. Characterization of the reaction products formed during the activation of bovine prothrombin. J Biol Chem (1974) 2.19
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood (2001) 2.15
Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest (2000) 2.13
Angiotensin II receptor blockade and effects on pulmonary hemodynamics and hypoxic pulmonary vasoconstriction in humans. Chest (1996) 2.10
Airway dysfunction in nasal polyposis: a spectrum of asthmatic disease? Clin Exp Allergy (2011) 2.06
Left ventricular systolic performance during acute hypoxemia. Chest (1995) 2.05
Interaction of coagulation factor Xa with human platelets. Proc Natl Acad Sci U S A (1977) 2.03
Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol (1996) 1.93
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax (2006) 1.86
Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med (1994) 1.86
Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. Am J Respir Cell Mol Biol (1998) 1.86
DYSTROPHIC MORPHOLOGY AND ITS SIGNIFICANCE. Science (1923) 1.82
Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol (1981) 1.82
C-reactive protein. A clinical marker in community-acquired pneumonia. Chest (1995) 1.77
Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax (1996) 1.77
Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax (1997) 1.75
Paradoxical down-regulation and desensitization of beta2-adrenoceptors by exogenous progesterone in female asthmatics. Chest (1997) 1.69
A polypeptide region of bovine prothrombin specific for binding to phospholipids. Proc Natl Acad Sci U S A (1973) 1.65
Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. Br J Clin Pharmacol (1999) 1.63
Prothrombin structure, activation, and biosynthesis. Physiol Rev (1977) 1.61
Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest (2001) 1.59
Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy (2001) 1.55
Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax (1997) 1.53
The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy (2009) 1.52
Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax (1993) 1.51
Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax (1996) 1.51
Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax (1997) 1.43
New perspectives on inhaled drug delivery and systemic bioactivity. Thorax (1995) 1.43
A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy (2002) 1.43
Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects. Chest (1996) 1.43
ON THE IMPROVEMENT OF MEDICAL TEACHING. Science (1912) 1.43
Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Thorax (1996) 1.43
Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol (2000) 1.40
Comment on: obtaining concomitant control of allergic rhinitis and asthma with intranasal corticosteroid. Allergy (2007) 1.39
Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax (1996) 1.38
Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax (1994) 1.38
Regular use of salbutamol in asthma. Lancet (2000) 1.38
Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device. Br J Clin Pharmacol (1993) 1.37
Studies on bovine factor X. II. Characterization of purified factor X. Observations on some alterations in zone electrophoretic and chromatographic behavior occurring during purification. Biochemistry (1968) 1.31
Factor Va-dependent binding of factor Xa to human platelets. J Biol Chem (1980) 1.28
Solution composition dependent variation in extinction coefficients for p-nitroaniline. Biochim Biophys Acta (1983) 1.25
Effects of hypercapnia on hemodynamic, inotropic, lusitropic, and electrophysiologic indices in humans. Chest (1996) 1.22
Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta 2-adrenoceptor blockade. Eur J Clin Pharmacol (1989) 1.21
Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline. Thorax (1992) 1.21
24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax (1999) 1.19
Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax (1995) 1.19
Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A (1989) 1.17
C-reactive protein in simple community-acquired pneumonia. Chest (1995) 1.17
The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin. J Biol Chem (1982) 1.16
Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Thorax (1995) 1.14
Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med (1997) 1.14
Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clin Endocrinol (Oxf) (1999) 1.13
Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci (Lond) (1992) 1.12
Ependymal brain cyst. Surg Neurol (1982) 1.11
Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. Thorax (1995) 1.11
Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med (1994) 1.10
The conversion of prothrombin to thrombin. II. Differentiation between thrombin- and factor Xa-catalyzed proteolyses. J Biol Chem (1974) 1.10
Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf (2000) 1.10
Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma. Am J Med (2000) 1.09
On the molecular-weight-dependence of the anticoagulant activity of heparin. Biochem J (1979) 1.09
Characterization of two glycoprotein variants of bovine factor X and demonstration that the factor X zymogen contains two polypeptide chains. Biochemistry (1972) 1.08
Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. J Allergy Clin Immunol (1998) 1.08
The action of thrombin on peptide p-nitroanilide substrates. Substrate selectivity and examination of hydrolysis under different reaction conditions. Biochim Biophys Acta (1983) 1.08
Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J (2010) 1.07
Beta-agonists and asthma. Lancet (1993) 1.07
The functional significance of vitamin K action. Difference in phospholipid binding between normal and abnormal prothrombin. J Biol Chem (1975) 1.07
Studies on bovine factor X. I. Large-sclae purification of the bovine plasma protein possessing factor X activity. Biochemistry (1968) 1.07
Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Thorax (1996) 1.06
Measurement of phospholipid monolayer surface potentials at a hydrocarbon-electrolyte interface. Biochim Biophys Acta (1979) 1.06
Dose-response of inhaled drugs in asthma. An update. Clin Pharmacokinet (1997) 1.06
Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects. Br J Clin Pharmacol (1992) 1.03
The conversion of prothrombin to thrombin. IV. The function of the fragment 2 region during activation in the presence of factor V. J Biol Chem (1974) 1.03
Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Chest (1999) 1.02
Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids. Lancet (1999) 1.02
Phospholipid monolayers at the hydrocarbon-electrolyte interface. The interrelation of film potential and film pressure. Biochim Biophys Acta (1979) 1.01
Binding of the products of prothrombin activation to human platelets. J Clin Invest (1975) 1.00
Comparison of methods for detecting specific IgM antibody in infants with congenital rubella. J Med Microbiol (1978) 0.99
Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax (1996) 0.99
Investigation of putative cardiac beta 3-adrenoceptors in man. Q J Med (1993) 0.97
Modulation of airway reactivity and peak flow variability in asthmatics receiving the oral contraceptive pill. Am J Respir Crit Care Med (1997) 0.97
A plausible mechanism for prothrombin activation by factor Xa, factor Va, phospholipid, and calcium ions. J Biol Chem (1974) 0.97
Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol (1994) 0.97
Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. Br J Clin Pharmacol (1999) 0.97
Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy (2000) 0.96
Gonadotrophin response after castration and selective destruction of the testicular interstitium in the normal and aspermatogenic rat. Acta Endocrinol (Copenh) (1978) 0.96
A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol. Chest (1999) 0.96
Pharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamol. Br J Clin Pharmacol (2001) 0.96
Influence of sex-steroid hormones on the regulation of lymphocyte beta 2-adrenoceptors during the menstrual cycle. Br J Clin Pharmacol (1994) 0.95